Natural Capsules Board Approves Q2 FY26 Results; Decides Against Subsidiary's Rights Issue
Natural Capsules' Board approved Q2 FY26 standalone and consolidated financial results. Standalone profit increased, but consolidated loss widened due to subsidiary's new operations. The company will not subscribe to Natural Biogenex's rights issue.
The announcement includes both standalone and consolidated financial results, with the consolidated results indicating a significant increase in net loss, which is a major financial event. Additionally, the strategic decision to not participate in the subsidiary's rights issue due to cash flow commitments is a notable corporate action with potential implications for the subsidiary's funding and the parent company's financial strategy.
The standalone financial results show positive growth in profit. However, the consolidated results report a substantial increase in net loss for the group, primarily due to a subsidiary's new operations not yet achieving full revenue potential. The decision not to subscribe to the subsidiary's rights issue due to cash flow constraints also indicates a challenging financial position for the group.
The Board of Directors of Natural Capsules Limited, at their meeting held on November 13, 2025, approved the Unaudited Consolidated & Standalone Financial Results for the quarter and half year ended September 30, 2025. * Standalone Financial Highlights (Quarter ended September 30, 2025): * Revenue from operations increased to ₹4,458.02 lakh from ₹4,102.98 lakh in the corresponding quarter last year. * Net Profit after tax significantly rose to ₹281.04 lakh compared to ₹92.22 lakh in the previous year. * Basic Earnings Per Share (EPS) improved to ₹2.72 from ₹0.90. * Standalone Financial Highlights (Half year ended September 30, 2025): * Revenue from operations increased to ₹8,882.31 lakh from ₹8,016.56 lakh in the corresponding half year last year. * Net Profit after tax significantly rose to ₹533.35 lakh compared to ₹238.13 lakh in the previous year. * Basic Earnings Per Share (EPS) improved to ₹5.16 from ₹2.32. * Consolidated Financial Highlights (Quarter ended September 30, 2025): * Revenue from operations increased to ₹4,580.27 lakh from ₹4,122.45 lakh in the corresponding quarter last year. * The company reported a Net Loss after tax of ₹-698.90 lakh, significantly wider than the ₹-61.22 lakh loss in the previous year. * Basic Earnings Per Share (EPS) was ₹-6.76, compared to ₹-0.60 in the previous year. * Consolidated Financial Highlights (Half year ended September 30, 2025): * Revenue from operations increased to ₹9,100.58 lakh from ₹8,040.79 lakh in the corresponding half year last year. * The company reported a Net Loss after tax of ₹-1,256.95 lakh, significantly wider than the ₹-0.90 lakh loss in the previous year. * Basic Earnings Per Share (EPS) was ₹-12.15, compared to ₹-0.01 in the previous year. * Reason for Consolidated Loss: The subsidiary, Natural Biogenex Private Limited, commenced commercial operations on March 31, 2025. While expenses for the quarter and half year ended September 30, 2025, have been charged to the Profit & Loss Account, the full revenue potential is yet to be achieved, resulting in a higher loss in the current period and making previous quarter figures not comparable. * Strategic Decision: The Board decided not to subscribe to the Rights Issue of Natural Biogenex Private Limited due to cash flow commitments related to ongoing projects. * The statutory auditors have issued an unmodified conclusion on both the standalone and consolidated unaudited financial results.
What to do with a filing like this
Natural Capsules Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natural Capsules Limited. Read the original for the full detail.